{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"EVOKE-SCLC-04","nct_id":"NCT06801834","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evoke-sclc-04-nct06801834. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EVOKE-SCLC-04","arms":[{"description":"Participants assigned to treatment group A will receive SG 10 mg/kg intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. Participants will receive study drug until progressive disease (PD), death, unacceptable toxicity, or another treatment discontinuation criterion is met.","label":"Treatment Group A: SG","type":"EXPERIMENTAL"},{"description":"Participants assigned to Treatment Group B will receive one of the following investigator selected treatments within a 21 day cycle:\n\n* Topotecan 1.5 mg/m² administered daily on Days 1 through 5, or\n* Lurbinectedin 3.2 mg/m² administered as an intravenous infusion on Day 1 (in countries/regions where lurbinectedin is approved and available).\n\nIn Japan, participants assigned to Treatment Group B may alternatively receive:\n\n• Amrubicin (available only in Japan) 40 mg/m² administered daily on Days 1 through 3 of a 21 day cycle.\n\nStudy treatment will continue until disease progression, death, unacceptable toxicity, or another protocol defined criterion for treatment discontinuation is met.","label":"Treatment Group B: Topotecan, or Lurbinectedin, or Amrubicin","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-10","type":"ESTIMATED"},"conditions":["Extensive Stage Small Cell Lung Cancer (ES-SCLC)"],"enrollment":{"count":695,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan (SG)","otherNames":["Trodelvy®","GS-0132","IMMU 132"],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Amrubicin (Japan only)","otherNames":[],"type":"DRUG"},{"name":"Lurbinectedin (regions/countries where approved and available)","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-20","lead_sponsor":"Gilead Sciences","official_title":"A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 4.5 years"}],"references":[],"start_date":{"date":"2025-04-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06801834"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evoke-sclc-04-nct06801834"}